Output Explorer

Every prompt in the paper, and what each model wrote back.

Return exactly ten single-sentence facts as JSON. Quality was judged pairwise; here you see the raw outputs and whether the JSON parsed.

13 of 1,000 prompts

ADEA · Q4 20252026-02-23 INLX · Q2 20252025-08-13 LPLA · Q3 20252025-10-30 RRGB · Q4 20252026-02-25 NXGL · Q3 20252025-11-11 COMP · Q2 20252025-07-30 MEDP · Q3 20252025-10-23 OSPN · Q1 20262026-04-30 HWC · Q2 20252025-07-15 RMNI · Q2 20252025-07-31 IAC · Q1 20262026-05-05 HZO · Q2 20262026-04-23 BBGI · Q3 20252025-11-10

Nearby prompts. All 1,000 Earnings calls prompts

PromptMEDP· Q3 2025 · call on2025-10-23· transcript 36,179 characters

Analyze the following earnings call transcript and extract the 10 most investor-relevant facts.

Each fact must:
- Be drawn only from the transcript (do not use any outside information).
- Be a single sentence capturing a specific, quantified insight relevant to investors.
- Avoid regurgitating the transcript verbatim; instead, synthesize and distill the information into investor-relevant facts.

Return only a JSON object with this exact structure (no markdown fences, no commentary):
{"facts": ["<fact 1>", "<fact 2>", ..., "<fact 10>"]}

The list must contain exactly 10 facts.

Transcript:
<transcript>
transcript redacted — the source calls are not publicly licensed
</transcript>

System prompt · identical for every setup

You are a financial analyst. You extract the most investor-relevant facts from earnings call transcripts to help investors anticipate the stock's reaction to the call.

Reference

No reference summary is published. Quality was judged pairwise by a separate model and is reported in aggregate on the main page.

Ours

10 facts · valid JSON

Medpace reported Q3 2025 revenue of $659.9 million, representing a 23.7% year-over-year increase driven by a therapeutic mix shift toward faster-burning studies.
The company achieved a record Q3 2025 EBITDA of $148.4 million, which grew 24.9% year-over-year with a margin of 22.5%.
Ending backlog as of September 30, 2025, stood at approximately $3 billion, a modest 2.5% increase from the prior year, despite strong booking activity.
Initial award notifications totaling work awarded but not yet in backlog increased approximately 30% year-over-year, suggesting a robust pipeline for future backlog refill.
Management updated full-year 2025 revenue guidance to a range of $2.48 billion to $2.53 billion, implying 17.6% to 20% growth over 2024 results.
For 2026, the company preliminarily expects low double-digit revenue growth and high single-digit or greater EBITDA growth.
Pass-through costs are expected to remain between 41% and 42% of revenue in 2026, with pass-throughs likely peaking in Q4 2025 before declining.
Share repurchases totaled approximately $913 million year-to-date in 2025, leaving $821.7 million remaining under the current authorization program.
Q3 2025 metabolic studies comprised approximately 30% of pass-through costs, up from 25% in the first half of the year, with this mix expected to level off in 2026.
Headcount growth is expected to accelerate in 2026 to support revenue guidance, with recent hiring concentrated primarily in the United States and India.

Aux 2015

Invalid JSONshown as written

Facts:

Medpace Holdings, Inc. (NASDAQ: MDP) reported third-quarter 2025 revenue of $659.9 million, representing a 23.7% year-over-year increase.
Net new business awards entering backlog in the third quarter increased 47.9% from the prior year to $789.6 million, resulting in a 1.20 net book-to-bill.
Ending backlog as of September 30, 2025, was approximately $3 billion, an increase of 2.5% from the prior year.
The company projects 2026 revenue to grow in the range of 17.6% to 20% over 2024 total revenue of $2.11 billion.
EBITDA for the third quarter was $148.4 million, representing a 24.9% increase compared to $118.8 million in the prior year.
Year-to-date EBITDA was $397.5 million, representing a 14.7% increase from the comparable prior year period.
EBITDA margin for the third quarter was 22.5%, compared to 22.3% in the prior year period.
Year-to-date EBITDA margin was 21.8%, compared to 22% in the prior year period.
EBITDA margins benefited from productivity and lower employee-related costs, offset by higher reimbursable costs.
Net income for the quarter was $111.1 million, representing a 15.3% increase compared to $96.4 million in the prior year period.
Net income per diluted share for the quarter was $3.86, compared to $3.01 in the prior year period.
The company generated $246.2 million in cash flow from operating activities, and its net days sales outstanding was negative 64.3 days.
During the quarter, the company repurchased approximately 14,649 shares for $4.5 million.
Year-to-date, the company repurchased 2.96 million shares or $912.9 million.
As of September 30, 2025, the company had $821.7 million remaining under its share repurchase authorization program.
Full-year 2025 revenue is expected in the range of $2.48 billion to $2.53 billion, representing growth of 17.6% to 20% over 2024 total revenue of $2.11 billion.
The company expects 2025 EBITDA to grow in the range of 13.5% to 15.6% compared to EBITDA of $480.2 million in 2024.
The company forecasts 2025 net income in the range of $431 million to $439 million.
This guidance assumes a full-year 2025 effective tax rate of 18.25% to 18.75%, interest income of $12.2 million and $29.5 million diluted weighted average shares outstanding.
Earnings per diluted share is now expected to be in the range of $14.60 to $14.86.
Guidance is based on foreign exchange rates as of September 30, 2025.
The company will now take questions from the audience.

PiT-FT 2015

Invalid JSONshown as written

<|assistant|>
<|assistant|>
<|assistant|>

The same 14-character fragment repeats 292 times until the token limit. Showing the first three.

ChronoGPT 2015

Invalid JSONshown as written


### Final Answer: